Caribou Biosciences Inc (CRBU)

$1.77 +0.05 (2.91%)
Market Cap 148.61M
Revenue (ttm) 9.99M
Net Income (ttm) -149.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,492.59%
Debt to Equity Ratio 0.00
Volume 1,006,400
Avg Vol 2,529,056
Day's Range N/A - N/A
Shares Out 93.47M
Stochastic %K 88%
Beta 2.61
Analysts Strong Sell
Price Target $9.88

Company Profile

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 982 6030
Address:
2929 7th Street, Suite 105, Berkeley, United States
deltabeta
deltabeta Jan. 7 at 9:06 PM
$ALT today I told you about $RCKT. Tomorrow it is $CRBU
0 · Reply
Peterson28
Peterson28 Jan. 7 at 6:57 PM
$CRBU Market is telling you this is so unloved. Management is so unqualified to run this company.
1 · Reply
3DBuilds
3DBuilds Jan. 7 at 12:21 PM
$BMY $CRBU $EDIT $NTLA $PRME
0 · Reply
JRLid
JRLid Jan. 6 at 8:10 PM
$CRBU Technical analysis https://www.investing.com/equities/caribou-biosciences-technical
1 · Reply
Peterson28
Peterson28 Jan. 6 at 8:01 PM
$CRBU Gene editing stocks show some signs of life today
2 · Reply
RocroBio
RocroBio Jan. 6 at 2:51 PM
$NTLA $BEAM $EDIT $CRBU
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 1:01 PM
$CRBU RSI: 33.33, MACD: -0.0918 Vol: 0.11, MA20: 1.72, MA50: 1.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DimebagDarrell_
DimebagDarrell_ Jan. 5 at 3:38 PM
$CRBU 🎯 Glad I sold half.
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 3 at 3:51 PM
$TNXP screw your courage to the sticking place, my fellow Tonix investors. 2026 is off to a strong start, and Point72’s arrival and significant stake is a very bullish sign. Here’s a nice Google AI summary. $CRBU is also undervalued in the competitive hem/onc cell therapy space. At first glance, what differntiates their deal with Tonix is that we have a company early in launch whereas most of their investments are still in the clinical stage. Cohen’s army at Point72 will expect to see Tonmya sales growth just like all of us. Hopefully they’ll also push Seth and the board to hire a real CFO 💎 👊
1 · Reply
JRLid
JRLid Jan. 3 at 1:58 PM
$CRBU For CB 011 the path so far reflects disciplined decision making rather than missteps. After the Pfizer investment in mid 2023 the CaMMouflage study progressed through dose escalation with a clear focus on safety and biology. In 2024 management chose to optimize the lymphodepletion regimen to improve persistence and depth of response, accepting a delay in timing to strengthen the eventual data. In early 2025 the pipeline was prioritized and disclosure was pushed to ensure the readout would be clinically meaningful. That decision was validated in November 2025 with a clear recommended dose and very strong efficacy in BCMA naive patients.
2 · Reply
Latest News on CRBU
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Dec 1, 2025, 4:05 PM EST - 5 weeks ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 2 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in Upcoming Investor Conferences

Nov 3, 2025, 5:15 PM EST - 2 months ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Nov 3, 2025, 11:48 AM EST - 2 months ago

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST - 2 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 3, 2025, 7:00 AM EST - 2 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Nov 2, 2025, 4:00 PM EST - 2 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Aug 25, 2025, 4:05 PM EDT - 4 months ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:05 PM EDT - 5 months ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:00 PM EDT - 8 months ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 8 months ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

May 6, 2025, 4:00 PM EDT - 8 months ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Apr 24, 2025, 4:15 PM EDT - 9 months ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect

Apr 10, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out

Apr 8, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation

Apr 6, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 10 months ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 10 months ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect

Mar 30, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation

Mar 27, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation

Mar 25, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out

Mar 20, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect

Mar 18, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 16, 2025, 10:00 AM EDT - 10 months ago

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation

Mar 13, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation

Mar 11, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 10 months ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Feb 24, 2025, 5:45 AM EST - 11 months ago

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 23, 2025, 9:27 AM EST - 11 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

Feb 20, 2025, 1:28 PM EST - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Feb 19, 2025, 10:22 AM EST - 11 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

Feb 15, 2025, 3:04 PM EST - 11 months ago

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

Jan 29, 2025, 10:51 AM EST - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences

deltabeta
deltabeta Jan. 7 at 9:06 PM
$ALT today I told you about $RCKT. Tomorrow it is $CRBU
0 · Reply
Peterson28
Peterson28 Jan. 7 at 6:57 PM
$CRBU Market is telling you this is so unloved. Management is so unqualified to run this company.
1 · Reply
3DBuilds
3DBuilds Jan. 7 at 12:21 PM
$BMY $CRBU $EDIT $NTLA $PRME
0 · Reply
JRLid
JRLid Jan. 6 at 8:10 PM
$CRBU Technical analysis https://www.investing.com/equities/caribou-biosciences-technical
1 · Reply
Peterson28
Peterson28 Jan. 6 at 8:01 PM
$CRBU Gene editing stocks show some signs of life today
2 · Reply
RocroBio
RocroBio Jan. 6 at 2:51 PM
$NTLA $BEAM $EDIT $CRBU
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 1:01 PM
$CRBU RSI: 33.33, MACD: -0.0918 Vol: 0.11, MA20: 1.72, MA50: 1.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DimebagDarrell_
DimebagDarrell_ Jan. 5 at 3:38 PM
$CRBU 🎯 Glad I sold half.
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 3 at 3:51 PM
$TNXP screw your courage to the sticking place, my fellow Tonix investors. 2026 is off to a strong start, and Point72’s arrival and significant stake is a very bullish sign. Here’s a nice Google AI summary. $CRBU is also undervalued in the competitive hem/onc cell therapy space. At first glance, what differntiates their deal with Tonix is that we have a company early in launch whereas most of their investments are still in the clinical stage. Cohen’s army at Point72 will expect to see Tonmya sales growth just like all of us. Hopefully they’ll also push Seth and the board to hire a real CFO 💎 👊
1 · Reply
JRLid
JRLid Jan. 3 at 1:58 PM
$CRBU For CB 011 the path so far reflects disciplined decision making rather than missteps. After the Pfizer investment in mid 2023 the CaMMouflage study progressed through dose escalation with a clear focus on safety and biology. In 2024 management chose to optimize the lymphodepletion regimen to improve persistence and depth of response, accepting a delay in timing to strengthen the eventual data. In early 2025 the pipeline was prioritized and disclosure was pushed to ensure the readout would be clinically meaningful. That decision was validated in November 2025 with a clear recommended dose and very strong efficacy in BCMA naive patients.
2 · Reply
3DBuilds
3DBuilds Jan. 3 at 1:48 PM
$NTLA $CRBU $EDIT $PRME $BMY Here we go 💯
2 · Reply
RocroBio
RocroBio Jan. 3 at 2:29 AM
$CRBU Cheers from Costa Rica. 6 months until Pfizer loses ROFN on Caribou. Hang tight everyone it’s gonna be a choppy 6 months 🫡
0 · Reply
Itsokman
Itsokman Jan. 2 at 4:40 PM
$CRBU They don’t make any money
1 · Reply
Reneejordan001
Reneejordan001 Jan. 2 at 3:36 PM
$CRBU WTF is the problem here?
0 · Reply
ChicagoJoe20
ChicagoJoe20 Jan. 2 at 12:44 AM
$CRBU invivo > allogenic exvivo? 🤔
1 · Reply
Sumner36
Sumner36 Jan. 1 at 9:59 PM
$CRBU LinkedIn Post
0 · Reply
Ewak21
Ewak21 Jan. 1 at 6:28 PM
$CRBU
0 · Reply
Peterson28
Peterson28 Dec. 31 at 9:37 PM
$CRBU Rubbish CEO and BD.
1 · Reply
MagisterofMarkets
MagisterofMarkets Dec. 31 at 5:35 PM
$CRBU can someone plz tell me why we have zero institutional interest here? Best in class allogenic therapy has to be worth something to someone…
1 · Reply
HughGeez
HughGeez Dec. 31 at 5:04 PM
$CRBU We are hitting around a six-month low today. My theory for the latest dip is people are taking losses at the end of the year for tax purposes, but will jump back in next year. There is great upside it this stock and I am excited for 2026. Happy Year everyone, wishing you a healthy and prosperous 2026 (with CRBU a part of your portfolio).
1 · Reply
JRLid
JRLid Dec. 31 at 10:48 AM
$CRBU As 2025 comes to a close CRBU sits at an interesting inflection point, hovering right around the 200 day moving average. After a strong run earlier in the year and solid clinical validation, the recent dip feels less like a change in fundamentals and more like positioning. We have already seen meaningful Phase 1 data for both vispa cel and CB 011, FDA alignment on a pivotal Phase 3 path for vispa cel, and a balance sheet that supports operations into 2027. At this stage the science risk is largely behind us and the debate has shifted to execution, financing structure and timing. The weakness into year end may simply reflect tax loss harvesting and portfolio cleanup rather than any new negative information. That kind of pressure tends to be temporary, especially when it occurs near long term technical levels like the MA200.
1 · Reply
Peterson28
Peterson28 Dec. 31 at 4:36 AM
$CRBU They usually announce that during the first week of Jan. Wait few more days.
1 · Reply